NCT03033927View on ClinicalTrials.gov

Predicting Effective Therapy in Pancreatic Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

74

Participants

Timeline

Start Date

January 24, 2017

Primary Completion Date

January 24, 2026

Study Completion Date

January 24, 2026

Conditions
Pancreatic CancerPancreatic Adenocarcinoma
Interventions
DIAGNOSTIC_TEST

CTC isolocation and analysis

Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.

Trial Locations (4)

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

07920

Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03033927 - Predicting Effective Therapy in Pancreatic Cancer | Biotech Hunter | Biotech Hunter